World Journal of Surgery

, Volume 40, Issue 4, pp 982–986 | Cite as

The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution

  • Se-Jin BaekEmail author
  • Hyuk Hur
  • Byung-Soh Min
  • Seung-Hyuk Baik
  • Kang-Young Lee
  • Nam-Kyu Kim
Original Scientific Report



Bone metastasis in patients with colorectal cancer (CRC) is very rare, and data are extremely lacking. We aimed to evaluate the characteristics of bone metastasis in patients with CRC.

Materials and methods

We performed a chart review of 63 patients (1.1 %) with bone metastasis among 5479 patients who underwent surgery for CRC.


Most patients were stage 3 (17.5 %) or 4 (73.0 %), and 32 patients (50.8 %) were diagnosed with bone metastasis at initial diagnoses of CRC. Thirty-one patients developed bone metastasis during the follow-up period with median 10.1-month interval. PET–CT was most frequently used for the diagnosis of bone metastasis (71.4 %), and the spine was the most commonly involved site (77.8 %). Most patients had multiple bone metastases (73.0 %) and other metastases (87.3 %). Bone pain was the most common skeletal-related event (25.4 %), and patients were treated with radiation (25.4 %), surgery (14.3 %), or bisphosphonate (6.3 %). The median survival time was 17.8 months, and the 5-year survival rate was 5.7 %. In the multivariate analysis, the risk factors for survival included initial bone metastasis (hazard ratio [HR] 3.03; P < 0.001) and bone metastasis from colon cancer (HR 1.87; P = 0.04).


Bone metastasis in patients with CRC is extremely rare and shows poor prognosis.


Colorectal Cancer Bone Metastasis Zoledronic Acid Bone Pain Pamidronate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Author contributions

Baek SJ acquired, analyzed, and interpreted the data and constructed the manuscript; Kim NK conceptualized this paper; Hur H, Min BS, Baik SH, and Lee KY reviewed the manuscript.

Compliance with ethical standards


The authors have no source of support in the form of equipment, drugs, or grants to declare.


  1. 1.
    O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMedGoogle Scholar
  2. 2.
    Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113CrossRefPubMedGoogle Scholar
  3. 3.
    Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ (2009) Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 9:274PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254CrossRefPubMedGoogle Scholar
  5. 5.
    Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594CrossRefPubMedGoogle Scholar
  6. 6.
    Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603CrossRefPubMedGoogle Scholar
  7. 7.
    Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001–1010CrossRefPubMedGoogle Scholar
  8. 8.
    De Marinis F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4:1280–1288CrossRefPubMedGoogle Scholar
  9. 9.
    Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMedGoogle Scholar
  10. 10.
    Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29:1146–1150PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Ganry O, Lapotre-Ledoux B, Fardellone P, Dubreuil A (2008) Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 23:467–473CrossRefPubMedGoogle Scholar
  12. 12.
    Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581CrossRefPubMedGoogle Scholar
  13. 13.
    Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799–802PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Nozue M, Oshiro Y, Kurata M et al (2002) Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 9:109–112PubMedGoogle Scholar
  15. 15.
    Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D (2007) Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 16:539–542CrossRefGoogle Scholar
  16. 16.
    Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMedGoogle Scholar
  17. 17.
    Rotolo N, De Monte L, Imperatori A, Dominioni L (2007) Pulmonary resections of single metastases from colorectal cancer. Surg Oncol 16:S141–S144CrossRefPubMedGoogle Scholar
  18. 18.
    Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR (2011) Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol 2:326–328PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Santini D, Tampellini M, Vincenzi B et al (2012) Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:2072–2077CrossRefPubMedGoogle Scholar
  20. 20.
    Fairchild A, Barnes E, Ghosh S et al (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75:1501–1510CrossRefPubMedGoogle Scholar
  21. 21.
    Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317–7325CrossRefPubMedGoogle Scholar
  22. 22.
    Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405CrossRefPubMedGoogle Scholar
  24. 24.
    Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMedGoogle Scholar
  25. 25.
    Hattori S, Miyakawa H, Okuda K, Kudo K, Noguchi T (2004) Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases. Gan To Kagaku Ryoho 31:271–274PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2015

Authors and Affiliations

  • Se-Jin Baek
    • 1
    Email author
  • Hyuk Hur
    • 1
  • Byung-Soh Min
    • 1
  • Seung-Hyuk Baik
    • 1
  • Kang-Young Lee
    • 1
  • Nam-Kyu Kim
    • 1
  1. 1.Division of Colon and Rectal Surgery, Department of SurgeryYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations